Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Safety monitoring for GLP-1 therapy itself includes: Assessment for gastrointestinal adverse effects, which are common but usually transient Monitoring for signs of pancreatitis (severe, persistent abdominal pain) Vigilance for symptoms suggesting thyroid masses (neck lump, difficulty swallowing, persistent hoarseness) Regular review of glycaemic control in diabetic patients Blood pressure and cardiovascular risk factor assessment Monitoring for gallbladder disease (right upper abdominal pain, fever, jaundice) Eye examinations for people with diabetes, particularly those with pre-existing diabetic retinopathy Renal function checks, especially if experiencing severe gastrointestinal symptoms that could lead to dehydration If you have diabetes and take insulin or sulfonylureas, your doctor may reduce these doses when starting GLP-1 therapy to prevent hypoglycaemia
Human trial data are inconsistent but suggest variability between drugs and formulations: exenatide (Bydureon) reached 1%3% of peripheral levels in CSF (156), while another formulation of once-weekly exentide (Bcise) only achieved approximately 1% of peripheral levels detectable in CSF (61)
But reduced appetite does not automatically mean reduced nutrition
Intermittent adjustments often yield better results and minimize side effects
A research update on exendin-4 as a novel molecule against parkinson's disease
